29 August 2025
29 August 2025
Science may have outpaced logistics and scalability, but the cell and gene industry is performing admirably.
Novo has identified srRNA candidates as an avenue to return to its obesity and weight loss market perch.
Outlook’s wait to join the retinal disease market in the US goes on despite European market expansion plans.
The MHRA's endorsement of the oral therapy is based on the outcomes from two Phase III trials.
While 84% of products remain in early development, the four late-stage contenders are poised for regulatory approval in East Asia.
The authorisation is based upon results from the Phase III SELECT-GCA trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
